In 2022, 20 million people were diagnosed with cancer across the globe with 9.7 million deaths, and by 2050, global cancer cases are projected to reach 35 million—a stark reminder of the growing urgency for stronger prevention and treatment strategies*. But beyond the systems level, the impact of a cancer diagnosis is felt heaviest by the affected individual, their families, and wider communities. That's why the new theme of World Cancer Day, "United by Unique", focuses on seeing the person before the patient, placing people at the centre of their care, and their stories at the heart of the conversation**.
Technology, if developed and applied responsibly, is a powerful tool that can help diagnose cancer in difficult cases, select treatments with the highest probability of success, and predict personalised clinical outcomes. Concr was founded on the principle of individuality, developing technology to model molecular cancer biology of every person for precise treatment predictions.
This month we are celebrating some of our partners and the brilliant individuals who support us in our mission to enable precision therapy for all, and collectively rewrite the future of cancer care.
After completing her DPhil in radiation biology at the University of Oxford, Dr Somaiah became the first recipient of an ICR Clinician Scientist Fellowship award. Her research focuses on biological optimisation of radiotherapy by improving tumour response whilst minimising normal tissue toxicity, for a truly personalised approach.
Partner project: AI-VISION - an observational study validating Concr's predictive algorithm for patient prognostication and treatment stratification in Triple-Negative Breast Cancer.
Dr Cook is the Chief or Principal Investigator of > 20 different clinical studies. She has been awarded a NIHR Rosetrees Trust Advanced Fellowship focusing on cancer of unknown primary (CUP), alongside developing new treatments for multiple types of cancer.
Partner project: CUP-COMP - improving diagnostic accuracy for individuals with metastatic CUP using data from different diagnostic assays (whole genome sequencing and liquid biopsies) together with Concr's predictive analytics.
Jacqueline brings twenty years of experience in biobanking in large scale genomics programmes, multi-country clinical trials, and advanced analytics in leveraging data to improve healthcare outcomes for patients, while bringing health equity, equality and diversity to research and clinical practice.
Partner project: CariGenetics and Concr will combine resources to utilise clinical and molecular data from the diverse Caribbean population to improve predictive accuracy of therapeutic response in breast cancer patients.
Concr is proud to have a diverse partner network of private companies, healthcare organisations, and research institutions. Click here to learn more about our partnerships, or get in touch today at info@concr.co to discuss opportunities to collaborate.
* American Cancer Society (2025): https://pressroom.cancer.org/W....
** World Cancer Day: https://www.worldcancerday.org...
Back